Patents Assigned to Celltech R & D Limited
  • Patent number: 8304200
    Abstract: The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognizes an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: November 6, 2012
    Assignee: Celltech R&D Limited
    Inventors: Alastair David Griffiths Lawson, Meryn Ruth Griffiths
  • Patent number: 7989594
    Abstract: The present invention provides antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1. Also provided are antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1 to which one or more effector molecules are attached.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: August 2, 2011
    Assignee: Celltech R & D Limited
    Inventors: David Paul Humphreys, Sam Philip Heywood
  • Patent number: 7872103
    Abstract: The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: January 18, 2011
    Assignee: Celltech R & D, Limited
    Inventors: Leon Fernando Garcia-Martinez, Yuching Chen, Dawn Andrews
  • Patent number: 7850968
    Abstract: The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compounds that can modulate CD83 and the immune system.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: December 14, 2010
    Assignee: Celltech R&D Limited
    Inventors: Fred Ramsdell, Sean C Proll, Karen Staehling-Hampton, Mark W. Appleby, Leon Fernando Garcia-Martinez
  • Publication number: 20100249380
    Abstract: The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function.
    Type: Application
    Filed: February 3, 2010
    Publication date: September 30, 2010
    Applicant: CELLTECH R&D LIMITED
    Inventors: LEON FERNANDO GARCIA-MARTINEZ, YUCHING CHEN, DAWN ANDREWS
  • Patent number: 7771969
    Abstract: The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: August 10, 2010
    Assignee: Celltech R&D Limited
    Inventors: Alastair David Griffiths Lawson, Meryn Ruth Griffiths
  • Publication number: 20090269840
    Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
    Type: Application
    Filed: October 30, 2007
    Publication date: October 29, 2009
    Applicant: CELLTECH R&D LIMITED
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison
  • Publication number: 20090191200
    Abstract: The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.
    Type: Application
    Filed: November 24, 2008
    Publication date: July 30, 2009
    Applicant: CELLTECH R&D LIMITED
    Inventors: Mark Ian Christie, Richard James Mead, Martyn Kim Robinson, Stephen Edward Rapecki
  • Patent number: 7566771
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 28, 2009
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7531676
    Abstract: Bipolar lipids are described which are able to form complexes with polyanions. The lipids comprise a cationic head linked to a hydrophobic backbone and a hydrophilic tail and are capable of self assembly to form stable complexes in aqueous solutions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 12, 2009
    Assignee: Celltech R & D Limited
    Inventors: Michael Anthony William Eaton, Timothy John Norman, David Parker, Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall
  • Publication number: 20090042877
    Abstract: Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N? atom or a —C(Rb)? group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH? group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
    Type: Application
    Filed: August 7, 2008
    Publication date: February 12, 2009
    Applicant: CELLTECH R&D LIMITED
    Inventors: Daniel Christopher Brookings, Jeremy Martin Davis, Barry John Langham
  • Patent number: 7482452
    Abstract: This invention provides a class of 3-amino-7H-thieno[2,3-b]pyridin-6-one derivatives, substituted in the 7-position by an aryl, heteroaryl, cycloalkyl or heterocycloalkyl moiety, and in the 2-position by a specified range of substituent groups; also provided is a process for preparing those compounds, and the use thereof as intermediates in the manufacture of certain p38 MAP kinase inhibitors.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: January 27, 2009
    Assignee: Celltech R&D Limited
    Inventors: Graham Robert Evans, Ian Harold Smith, Neil Tremayne, Leighton Jones, Marianne Langston
  • Patent number: 7423047
    Abstract: Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N? atom or a —C(Rb)? group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH? group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: September 9, 2008
    Assignee: Celltech R&D Limited
    Inventors: Daniel Christopher Brookings, Jeremy Martin Davis, Barry John Langham
  • Publication number: 20080096957
    Abstract: The present invention provides an albumin-binding compound essentially of the following elements: a spacer group, a water-soluble bridging group, a fatty acid chain and an acidic group characterised in that the acidic group is attached to the distal end of the fatty acid chain. The invention also provides an albumin-binding compound to which one or more biologically active moieties are attached.
    Type: Application
    Filed: May 25, 2005
    Publication date: April 24, 2008
    Applicant: Celltech R&D Limited
    Inventors: Michael Eaton, Timothy Norman, John Porter
  • Publication number: 20080044817
    Abstract: The present invention provides a method for controlling the partitioning of a recombinant protein between the supernatant and the periplasm in E. coli host cell cultures wherein expression of the recombinant protein by said cells is under the control of an inducible system, which method comprises: a) providing an E. coli host cell culture b) changing the growth rate of the E. coli host cells c) inducing expression of the recombinant protein wherein steps (b) and (c) can be performed in any order or simultaneously; and subsequently d) determining the yield of recombinant protein in the culture supernatant and the E. coli host cell periplasm e) comparing the yield determined in step (d) with the yield determined when at least one other growth rate has been used in step (b) f) selecting a growth rate from the comparison made in step (e) in which the partitioning of the recombinant protein between the supernatant and the periplasm is most suited to the primary recovery of the recombinant protein.
    Type: Application
    Filed: September 2, 2004
    Publication date: February 21, 2008
    Applicant: Celltech R&D Limited
    Inventors: David John Glover, Mukesh Sehdev, Dominic Gambier Reeks
  • Patent number: 7323464
    Abstract: Compounds of formula (1) are described in which Ra and Rb is each independently a hydrogen atom or a group Rc, or Ra and Rb together form an oxo (?O) or thio (?S) group; X is a N atom or an optionally substituted CH group: Y is a —O— or —S— atom or —SO— or —SO2— group or an optionally substituted —CH2— or —NH— group with the proviso that when Ra and Rb together form an oxo (?O) or thio (?S) group Y is an optionally substituted —CH2— or —NH-group; L1 is a covalent bond or a linker atom or group; p is zero or the integer 1; Alk1 is an optionally substituted C1-10aliphatic or C1-10heteroaliphatic chain; n is zero the integer 1, 2 or 3 with the proviso that when n is zero Y is an optionally substituted —CH2— group; Ar is an optionally substituted C6-12aromatic or C1-9heteroaromatic group; m is zero or the integer 1, 2 or 3; q is zero or the integer 1 or 2; R1, Rc and Rd are hydrogen atoms or the substituents described in the patent specification; and the salts, solvates, hydrates and N-oxides thereof.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: January 29, 2008
    Assignee: Celltech R&D Limited
    Inventors: Jeremy Martin Davis, Barry John Langham, Manisha Naik, Daniel Christopher Brookings, Rachel Jane Cubbon, Richard Jeremy Franklin
  • Publication number: 20070269428
    Abstract: The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.
    Type: Application
    Filed: November 16, 2004
    Publication date: November 22, 2007
    Applicant: Celltech R&D Limited
    Inventors: Mark Christie, Richard Mead, Martyn Robinson, Stephen Rapecki
  • Publication number: 20070243564
    Abstract: The present invention provides an automated homogeneous assay for identifying an antibody-producing cell producing an antibody which binds to a selected antigen, especially a high yielding antibody-producing cell.
    Type: Application
    Filed: June 10, 2005
    Publication date: October 18, 2007
    Applicant: Celltech R&D Limited
    Inventors: Alastair Lawson, Simon Tickle
  • Patent number: 7261892
    Abstract: The present invention relates to the use of a polypeptide (CD27L) for diagnosis of epithelial-related cancers, in particular kidney cancer e.g. renal cell cancer and colorectal cancer, e.g. colon cancers, as well as in methods of treatment of such cancers.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: August 28, 2007
    Assignee: Celltech R&D Limited
    Inventor: Jonathan Alexander Terrett
  • Patent number: 7262050
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: August 28, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage